Results

RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/23346184http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/23346184http://www.w3.org/2000/01/rdf-schema#comment"

Introduction

Anti-neutrophil cytoplasmic antibodies specific for bactericidal/permeability-increasing protein (BPI-ANCA) are frequent in CF patients and mainly develop in response to infection with Pseudomonas aeruginosa. It is not known to what extent BPI-ANCA correlates to prognosis.

Objectives

To evaluate the prognostic value of IgA-BPI-ANCA, measured at the beginning of the study, for transplantation-free survival.

Methods

A cohort of 46 adult, nontransplanted CF patients was generated, 1995-1998, and characterized using Leeds criteria, lung function, and IgA-BPI-ANCA levels measured by ELISA. The cohort was followed until December 2009, using the combined endpoint of death or lung transplantation.

Results

Lung function and IgA-BPI-ANCA, but not Leeds criteria, were significantly associated with adverse outcome. No patient with normal lung function at baseline reached endpoint. Within 10 years 8/11 with high BPI-ANCA reached an endpoint compared to 3/17 ANCA-negative patients. A similar result was seen within the Leeds I group where 7 out of 9 BPI-ANCA-positive patients reached endpoint, compared to none of the 5 patients without BPI-ANCA.

Conclusions

IgA-BPI-ANCA is associated with adverse outcome among Pseudomonas aeruginosa infected CF patients, suggesting that BPI-ANCA is a biomarker of an unfavourable host-pathogen interaction."xsd:string
http://purl.uniprot.org/citations/23346184http://purl.org/dc/terms/identifier"doi:10.1155/2012/370107"xsd:string
http://purl.uniprot.org/citations/23346184http://purl.uniprot.org/core/author"Lindberg U."xsd:string
http://purl.uniprot.org/citations/23346184http://purl.uniprot.org/core/author"Carlsson M."xsd:string
http://purl.uniprot.org/citations/23346184http://purl.uniprot.org/core/author"Segelmark M."xsd:string
http://purl.uniprot.org/citations/23346184http://purl.uniprot.org/core/author"Lofdahl C.G."xsd:string
http://purl.uniprot.org/citations/23346184http://purl.uniprot.org/core/date"2012"xsd:gYear
http://purl.uniprot.org/citations/23346184http://purl.uniprot.org/core/name"Clin Dev Immunol"xsd:string
http://purl.uniprot.org/citations/23346184http://purl.uniprot.org/core/pages"370107"xsd:string
http://purl.uniprot.org/citations/23346184http://purl.uniprot.org/core/title"BPI-ANCA and long-term prognosis among 46 adult CF patients: a prospective 10-year follow-up study."xsd:string
http://purl.uniprot.org/citations/23346184http://purl.uniprot.org/core/volume"2012"xsd:string
http://purl.uniprot.org/citations/23346184http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/23346184
http://purl.uniprot.org/citations/23346184http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/23346184
http://purl.uniprot.org/uniprot/#_B4DKH6-mappedCitation-23346184http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/23346184
http://purl.uniprot.org/uniprot/#_P17213-mappedCitation-23346184http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/23346184
http://purl.uniprot.org/uniprot/P17213http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/23346184
http://purl.uniprot.org/uniprot/B4DKH6http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/23346184